Albemarle Plunges to Lowest in Nearly Four Years as Lithium Prices Keep Sliding
Solaris Expects Q2 Revenue To Be $70M - $75M (Est $62.65M) And Adjusted EBITDA To Be $20M - $21M
Solaris Expects Q2 Revenue To Be $70M - $75M (Est $62.65M) And Adjusted EBITDA To Be $20M - $21
Solaris Oilfield Infrastructure Agrees To Acquire Mobile Energy Rentals LLC For $200M
MER is a premier provider of distributed power solutions serving the energy and commercial & industrial ("C&I") end-markets.Transaction consideration includes $60 million of cash and the issuance of
MarineMax Gains After Island Capital Offers to Buy Yachting, Marina Business
UBS Maintains Neutral on Tronox Holdings, Lowers Price Target to $18
UBS analyst Joshua Spector maintains Tronox Holdings (NYSE:TROX) with a Neutral and lowers the price target from $19 to $18.
Tronox Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 14.07% UBS $19 → $18 Maintains Neutral 06/07/2024 39.42% Mizuho → $22 Initiates Coverage On →
WD-40 Q3 2024 Earnings Preview
E2open Parent Holdings Q1 2025 Earnings Preview
AZZ Q1 2025 Earnings Preview
PriceSmart Q3 2024 Earnings Preview
If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today
Riot Platforms (NASDAQ:RIOT) has outperformed the market over the past 5 years by 19.89% on an annualized basis producing an average annual return of 32.96%. Currently, Riot Platforms has a market
Trading Halt: Halt Status Updated at 5:15:00 PM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 5:15:00 PM ET: Quotation Resumption: News and Resumption
Arcutis Gets FDA Approval for Zoryve for Atopic Dermatitis
Benzinga Founder Jason Raznick On Meme Stocks, Importance Of Diversification: 'Didn't Want To Lose A Generation Of Investors'
The rise of meme stocks in recent years has led to more investing education — and some investors realizing they need to diversify.What Happened: Benzinga founder and Chairman Jason Raznick shared
UBS Maintains Neutral on LSB Industries, Lowers Price Target to $8.75
UBS analyst Joshua Spector maintains LSB Industries (NYSE:LXU) with a Neutral and lowers the price target from $9.25 to $8.75.
LSB Industries Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 16.82% UBS $9.25 → $8.75 Maintains Neutral 05/29/2024 46.86% Deutsche Bank $9 → $11 Maintains
Arcutis Biotherapeutics Says FDA Approved SNDA For ZORYVE (Roflumilast) Cream, 0.15%, For Treatment Of Mild To Moderate Atopic Dermatitis In Adult And Pediatric Patients 6 Years Of Age And Older
ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been specifically developed to be a treatment option for long-term disease
(HLVX) - Analyzing HilleVax's Short Interest
HilleVax's (NYSE:HLVX) short percent of float has risen 14.66% since its last report. The company recently reported that it has 1.55 million shares sold short, which is 20.02% of all regular shares
Peering Into Boot Barn Holdings's Recent Short Interest
Boot Barn Holdings's (NYSE:BOOT) short percent of float has fallen 6.09% since its last report. The company recently reported that it has 3.02 million shares sold short, which is 11.87% of all
Kura Sushi Breaks Even in FQ3 as Higher Expenses Eat Away at Sales